Venture NAV Tracker / Private company
X4 Pharmaceuticals, Inc.
Headquarters—
Founded—
Last known round—
Reported valuation—
+2631.5% equity-mark dispersion. Hercules Capital, Inc. carries X4 Pharmaceuticals, Inc. at $0.15/share; Hercules Capital, Inc. carries it at $4.12/share. Review dates and security types before treating those marks as directly comparable.
Cross-fund comparison
Equity & warrant marks
One latest disclosed mark per fund.
| Fund | Fair value | Security / basis | Implied price / share | Mark age vs round | Methodology / filing |
|---|---|---|---|---|---|
| HTGCHercules Capital, Inc. | $215KMar 31, 2026 · source ↗ | equityFair Value | $4.12Not comparable — different security type or share classMar 31, 2026 · source ↗ | —Mar 31, 2026 · source ↗ | 10-Q 2026-03-31 ↗ |
| HTGCHercules Capital, Inc. | $7KMar 31, 2026 · source ↗ | warrantFair Value | $0.15Not comparable — different security type or share classMar 31, 2026 · source ↗ | —Mar 31, 2026 · source ↗ | 10-Q 2026-03-31 ↗ |
Cross-fund comparison
Debt investments
One latest disclosed debt mark per fund.
| Fund | Security type / basis | Principal | Fair value | FV / principal | Rate | Maturity | Mark age vs round | Non-accrual |
|---|---|---|---|---|---|---|---|---|
| HTGCHercules Capital, Inc. | senior secured loanFair Value — Senior Secured | $75MMar 31, 2026 · source ↗ | $76.7MMar 31, 2026 · source ↗ | 102.2%Mar 31, 2026 · source ↗ | Prime + 3.15 %, Floor rate 10.15 %, 3.72 % Exit FeeMar 31, 2026 · source ↗ | Jul 1, 2027Mar 31, 2026 · source ↗ | —Mar 31, 2026 · source ↗ | NoMar 31, 2026 · source ↗ |
Historical marks
Reported fair value by fund
Each bar is a disclosed position-quarter.